This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Behind The Success - Research Report On Corcept Therapeutics Inc. And Dyax Corp.

Stocks in this article: CORTDYAX

NEW YORK, January 23, 2013 /PRNewswire/ --

After a less than satisfying launch of its flagship product Korlym - a treatment for Cushing's syndrome - resulting in a sharp drop in the stock price, drug developer Corcept Therapeutics Inc. (NASDAQ:CORT) [ Full Research Report] [1] has bounced back with an influx of buyers and renewed sentiment from analysts.

The company's stock price fell more than half in November last year from $2.50 to just $1.32 as sales of Korlym underperformed due to subpar marketing. Losses reached up to a whopping $8.3 million and only turned sales at less than $2 million. This year, the price rallied back up to $2 with a price target of $3 and was given a "buy" rating from Janney Capital.

Korlym is so far the only available drug for Cushing's syndrome patients in the market, and is granted orphan drug status by the FDA - giving it an additional two years of exclusivity on the market. This mainly triggered the interest of investors, who helped raise Corcept's stock price to as high as $4.90 in early 2012.

Dyax Corp. (NASDAQ:DYAX) [ Free Research Report] [ 2 ], a developer of Kalbitor - a drug that treat patients with hereditary angioedema (HAE) - has been downgraded by Zacks to a "neutral" rating from "outperform." The stock price is up by close to 2 percent at $3.65, and has a target price of $3.90.

The company recently updated Kalbitor (aka ecallantide) data from both HAE patients and HAE patients with abdominal attacks. The drug is indicated for the treatment of acute attacks of HAE in patients 16 years of age and older. Its approval is based on the results of two placebo-controlled Phase 3 clinical studies, known as EDEMA3 and EDEMA4. Patients having an HAE attack at any part of the body, with at least one moderate or severe symptom, are treated with 30 mg subcutaneous KALBITOR or placebo.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,399.67 +19.26 0.12%
S&P 500 1,904.01 +17.25 0.91%
NASDAQ 4,316.0740 +57.6360 1.35%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs